This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aprela, Bazedoxifene and Premarin, Bazedoxifene and conjugated estrogens (CE), BZA/CE, Duavive (EU)
Description: Aprela is a tissue selective estrogen complex combination of bazedoxifene and conjugated estrogens. Bazedoxifene is a selective estrogen receptor modulator, or SERM.
Deal Structure: In 1994, Ligand entered into a research and development collaboration with Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products (AHP), to discover and develop drugs that interact with estrogen receptors (ERs) or progsterone receptors (PRs) for use in HRT, anti-cancer therapy, gynecological diseases, and central nervous system disorders associated with menopause and fertility control. AHP has since changed its name to Wyeth. Ligand granted Wyeth exclusive worldwide rights to all products discovered in the collaboration that are agonists or antagonists to the PR and ER for application in the fields of women's health and cancer therapy. In May 1996, Wyeth-Ayerst exercised its option to expand its collaboration in women's health to include the area of treatment or prevention of osteoporosis through ER agonists.
In March 2002, Ligand announced an agreement with Royalty Pharma AG, which purchased rights to a share of future payments from Ligand's...See full deal structure in Biomedtracker
Partners: Ligand Pharmaceuticals, Inc. Royalty Pharma AG
Additional information available to subscribers only: